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Demonstrating the practical value of public research has been an important subject in science
policy. Here we present a detailed study on the evolution of the citation linkage between life science
related patents and biomedical research over a 37-year period. Our analysis relies on a newly-created
dataset that systematically links millions of non-patent references to biomedical papers. We find a
large disparity in the volume of science linkage among technology sectors, with biotechnology and
drug patents dominating it. The linkage has been growing exponentially over a long period of time,
doubling every 2.9 years. The U.S. has been the largest producer of cited science for years, receiving
nearly half of the citations. More than half of citations goes to universities, and the cited papers are
likely to be basic research. The U.S. National Institute of Health continues to be a major funder
of cited science. For the majority of companies, more than half of citations in their patents are
authored by public research. Taken together, these results indicate a continuous contribution of
public science to private sector inventions.
Keywords: patent-to-paper citation; non-patent reference; science-technology interaction; biomedical re-
search; public science
I. INTRODUCTION
There is a longstanding policy interest in unraveling
how knowledge generated from public research is used in
the private-sector. Studies towards this goal have heavily
focused on patent data and considered citations between
patents as evidence of knowledge flow. Despite some crit-
icism [7], such notion has been widely accepted in the
literature. Consequently, substantial attention has been
paid to patents assigned to universities and other pub-
lic organizations, examining how those patents are cited
by other patents, especially by patents from companies
[14, 16].
University patents, however, only account for a small
portion of granted patents, and the main products of
public research are scholarly papers rather than patents.
Just as patents, papers can also be cited by patents,
and indeed both the cited patents and cited papers are
served as the “prior art” of a patent application, playing
a significant role for patent examiner to determine the
patentability of the application. While there has been
a large literature on the patent-to-patent citation link-
age, studies about patent-to-paper linkage have been rel-
atively scarce, especially systematic studies, which is the
goal of this paper.
Our primary interest in this work is in the life science
sector. The last several decades have seen an unprece-
dented rapid progress of life science, both in basic sci-
entific discoveries and clinical medicine. Recent studies
have suggested that biotechnology and pharmaceutical
patents have been the main driver for the overall growth
of patents and exhibit a particularly prominent “science
linkage” [8]. This has prompted us to ask: How has
the patent-to-paper citation linkage of life science patents
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changed over time? In particular, we aim to answer the
following lines of research questions:
1. How has the amount of science linkage changed over
time? Does the change vary across different tech-
nology classes?
2. On the cited side of the linkage, which countries
and types of institutions produce the cited papers?
Whether basic or applied research are more likely
to be cited?
3. On the citing side, to what extent company patents
cite public science?
These questions are important due to their high relevance
to the policy community. Although the study of science
linkage of patents has a long history, initiated by Narin
and his colleagues in the 1980s [6, 10, 11], an up-to-date
“status report” of science linkage has been lacking in the
literature, partially due to the daunting task of resolv-
ing non-patent references to corresponding scholarly pa-
pers. Even in Narin’s landmark study [10], the analyzed
patents were granted in two two-year periods (1987–1988
and 1993–1994). By contrast, our analysis covers patents
from 1976 to 2012. Such a large-scale corpus allows us to
probe how the science linkage has changed over time. By
using a large sample over a 36-year period, we contribute
to the literature a systematic accounting of linkage from
technology to science.
II. DATA AND METHODS
Sample selection: The NBER patent database [2]
has been one of the major sources for information
about U.S. patents. However, it only covers patents
granted until 2006, whereas we want to extend to later
patents. We therefore used patent data directly from the
USPTO and parsed the downloaded XML files (https:
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2TABLE I. Top 20 countries (or territories) with most patents.
Country Patents % Country Patents %
US 605, 875 55.7 TW 9, 849 0.9
JP 156, 491 14.4 SE 9, 192 0.8
DE 87, 127 8.0 BE 7, 883 0.7
FR 35, 505 3.3 IL 6, 825 0.6
GB 33, 274 3.1 AU 6, 388 0.6
CA 20, 691 1.9 DT 5, 361 0.5
CH 17, 865 1.6 JA 4, 847 0.4
KR 14, 901 1.4 DK 4, 816 0.4
IT 14, 376 1.3 FI 4, 051 0.4
NL 10, 794 1.0 AT 3, 476 0.3
//bulkdata.uspto.gov/) to obtain bibliographic infor-
mation of patents. The NBER dataset instead is used as
an auxiliary source when we infer various attributes of
patents.
As we are interested in science-technology linkage in
the life science domain, we need to select life science
patents. In doing this, we note that there is an inherent
trade-off regarding sample coverage. On one hand, it
may not be desirable to narrow our analysis to, for exam-
ple, patents about drugs that treat certain diseases. On
the other, selecting patents from other domains, such as
the software industry, may bias our statistics about sci-
ence linkage, since those patents seldom cite biomedical
papers. Here we leverage the categorization developed
by NBER [2], which segments patents into six categories.
We define life science patents as those belonging to one
of the two NBER technological categories, namely
Chemical (Category 1) and Drugs & Medical (Category
3). Operationally, we selected not-withdrawn (https:
//www.uspto.gov/patents-application-process/
patent-search/withdrawn-patent-numbers), utility
patents granted between 1976 and 2012 whose pri-
mary, three-digit USPC (U.S. Patent Classification)
technology codes are in the 92 codes corresponding to
the two NBER categories (Appendix 1 in [2]). The
final sample used in our study consists of 1, 088, 650
patents. Patents that are not included into our sample
are from the following NBER categories: Computers &
Communications (Category 2), Electrical & Electronic
(Category 4), Mechanical (Category 5), and Others
(Category 6).
Country origin of patent: To examine whether sci-
ence linkage varies across patents from different coun-
tries, we need to identify the country origin of a
patent. We do so by using the residence of the
first inventor, a standard practice used in the lit-
erature [1, 2]. USPTO also employs this method
to, for example, report patent summary statistics
by country (https://www.uspto.gov/web/offices/
ac/ido/oeip/taf/stcasg/regions_stcorg.htm). For
a tiny portion (0.63%) of patents whose country of origin
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FIG. 1. Distribution of types of assignees.
cannot be determined through this way, which is due to
missing data of the first inventor’s address, we use the
NBER data to locate the country.
Table I lists the top 20 countries that have the largest
share of patents, which in total contribute to 97.3% of
all patents in our cohort. It is clear that the US patent
system has granted life science patents from inventors
originated from diverse countries, although US accounts
for more than half of the patents.
Type of patent assignee: To study how the types of
assignees may affect citations to scientific papers, we need
to classify patent assignees. To do this, we again leverage
the NBER patent dataset that has already classified as-
signees of patents in 1976–2006 into one of the following
six types: corporation, university, institute, government,
hospital, and individual. For later patents, we assign the
type based on the exact match of assignee names. If this
fails, we then classify by checking the role of the assignee
provided by USPTO, whether the assignee name is the
same as an applicant, and whether it contains certain
keywords (e.g., “Ltd”, “University”). There are 9.76%
patents without any assignee listed.
Figure 1 gives a side-by-side comparison of the decom-
position of the types of assignees for both chemical and
drugs & medical (DM) patents. Not surprisingly, the
overwhelmingly majority of patents are assigned to com-
panies. A larger fraction of DM patents, however, come
from universities. Many previous works have linked this
to the Bayh–Dole Act that permits universities to own
inventions that are funded by government [9].
Non-patent references in patent: Each and every
NPR cited in the patents has been resolved previously to
determine whether and which MEDLINE paper it refers
to, with a high accuracy obtained [3]. MEDLINE is per-
haps the most widely used database for the biomedical
research literature, curated and maintained by the US
National Library of Medicine (NLM). It is publicly avail-
able and provides a variety of meta data about papers
indexed there, including common bibliographic informa-
3tion like authors, affiliations, journal, publication year,
funding, etc. It also provides domain specific information
like Medical Subject Headings (MeSH). Moreover, many
additional resources that we rely on have been built on
top of MEDLINE, and literature has been using MED-
LINE for innovation study, such as operationalization of
the triple-helix model based on MeSH terms [13].
Country and institution type of papers: To un-
derstand how public science contributes to knowledge
cited in patents, we need to classify the types of insti-
tutions of papers. However, an important question be-
fore the classification is which author’s (or authors’) af-
filiation we should use, as modern science has become a
collaboration endeavor [17]. Here we choose to look at
only the first-author’s affiliation for two reasons. First, as
stated from the NLM, “until 2014, only the affiliation of
the first author was included,” (https://www.nlm.nih.
gov/bsd/mms/medlineelements.html#ad) and the first
author’s affiliation was not included until 1988. This lim-
itation is also reflected in the data: 87% of the 218, 483
papers cited in patents and without author affiliations
were published before 1988. Second, in biomedical re-
search, it is generally accepted that the first and the last
author get the most credit of a paper for performing and
supervising the research, respectively, and the two au-
thors share the same affiliations in most cases.
From the text of the first author’s affiliation, we
seek to extract the country and institution type infor-
mation. This task, fortunately, has been fulfilled by
an online tool called MapAffil (http://abel.lis.
illinois.edu/cgi-bin/mapaffil/search.py; [15]). It
returns geography information and institution type of the
input MEDLINE paper and has a reported accuracy of
97.7%. MapAffil classifies institutions into eight cate-
gories, namely educational, hospital, educational hospi-
tal, organization, commercial, government, military, and
unknown. For our study, we merge educational hospital
into educational, since teaching hospitals still serve the
education role for training medical students. Further-
more, we combine the organization, government, and mil-
itary categories into a single one, called public research
organization (PRO), because we primarily concern about
whether or not cited research are performed by com-
panies. Previous studies have also employed a similar
procedure [1]. Therefore, there are five types of institu-
tions of papers, namely educational (EDU), PRO, hospi-
tal (HOS), commercial (COM), and unknown (UNK).
Funding support of papers: An ongoing effort in
the study of the patent-to-paper citation linkage is to un-
derstand to what extent cited papers are supported by
public funding. We retrieve this information from the
paper meta data provided in the MEDLINE database.
First, we determine whether a paper is funded by the
US government by looking at whether the “Publication
Type” field has any of the following four terms: “Re-
search Support, U.S. Gov’t, Non-P.H.S.”, “Research Sup-
port, U.S. Gov’t, P.H.S.”, “Research Support, N.I.H.,
Extramural”, and “Research Support, N.I.H., Intramu-
ral”. Second, we determine whether a paper is supported
by the NIH by looking at the “Grant List” field and fur-
ther record which NIH institutes support the paper.
“Basicness” of papers: A repeatedly occurring as-
sumption in the literature about the role of public science
is that public science institutions conduct basic science,
while private firms perform applied research by utilizing
findings from basic research. Yet, few studies have ex-
amined to some extent papers cited in patents are basic
research, possibly because of the difficulty in the oper-
ationalization of the two notions to papers. One no-
table exception is [6] that used the four-level classification
scheme developed by the CHI Research in the 1970s [12].
The scheme assigns journals to one of the four categories,
which are, from the most basic to the most applied, “ba-
sic research”, “clinical investigation”, “clinical mix”, and
“clinical observation”. In this study, however, we do not
adopt this method for four reasons. First, we are not
aware the scheme is publicly available. Second, it re-
mains unclear whether a scheme developed in the 1970s
is still applicable nowadays, with numerous journals es-
tablished since then. Third, the scheme only considers
journals indexed in the SCI, while many MEDLINE jour-
nals are not there. Lastly and most importantly, the
scheme operates on journals rather than papers. One
immediate implication of this is that papers published
in all the journals belonging to the same category have
the same “basicness.” This is problematic, because many
biomedical journals publish qualitatively different types
of research, which can be basic or applied. As an exam-
ple, Circulation, a prestige journal with a 2017 Impact
Factor of 18.88, “publishes [...] related to cardiovascular
health and disease, including observational studies, clin-
ical trials, epidemiology, health services and outcomes
studies, and advances in basic and translational research”
(https://www.ahajournals.org/circ/about).
Here we use a method that was recently proposed to
identify translational science in biomedicine [4]. Trans-
lation science is research that “translate” basic scientific
discoveries (bench-side or basic research) to clinical ap-
plications (bed-side or applied research). The method
quantifies the basicness of papers directly. It results in a
paper-level indicator called level score (LS) ranging from
-1 to 1, with LS closer to -1 meaning that the paper
is, by construction, more basic and 1 more applied. The
method learns similarities between MeSH terms based on
their co-occurrences among papers, using modern repre-
sentation learning techniques. It then identifies an axis
that points from basic science terms to applied ones. The
basicness of a MeSH term is its projected position onto
the axis, expressed as the cosine similarity between the
axis vector and the term vector. The LS of a paper is the
average basicness of its MeSH terms. The method has
been validated and is consistent with Narin’s four-level
classification and other existing methods.
4TABLE II. Summary statistics of non-patent references (NPRs) cited by U.S. life science utility patents 1976–2012, grouped
by their NBER categories. SNPR refers to an NPR that corresponds to a MEDLINE paper.
NBER Category 1: Chemical
Patents Total Mean SNPRs by
Sub-cat Name All w/ SNPRs NPRs SNPRs All w/ SNPRs
11 Agriculture, food, textiles 22, 166 1, 019 54, 183 2, 853 0.129 2.800
12 Coating 58, 326 1, 873 127, 440 9, 402 0.161 5.020
13 Gas 20, 196 319 32, 179 1, 350 0.067 4.232
14 Organic compounds 91, 301 26, 538 686, 384 291, 540 3.193 10.986
15 Resins 105, 960 15, 667 585, 437 288, 730 2.725 18.429
19 Miscellaneous 384, 434 20, 049 827, 008 123, 405 0.321 6.155
Total: 682, 383 65, 465 2, 312, 631 717, 280 1.051 10.957
NBER Category 3: Drugs & Medical
Patents Total Mean SNPRs by
Sub-cat Name All w/ SNPRs NPRs SNPRs All w/ SNPRs
31 Drugs 158, 665 89, 008 2, 225, 049 1, 395, 016 8.792 15.673
32 Surgery & medical instruments 137, 981 28, 975 668, 424 274, 526 1.990 9.474
33 Biotechnology 79, 148 63, 625 1, 618, 241 1, 141, 578 14.423 17.942
39 Miscellaneous 30, 473 5, 748 123, 833 46, 377 1.522 8.068
Total: 406, 267 187, 356 4, 635, 547 2, 857, 497 7.034 15.252
III. RESULTS
A. Summary statistics
Table II reports the overall statistics of NPRs cited in
the 1, 088, 650 patents in our sample, grouped by their
NBER subcategories. The first group of statistics in
Table II concerns about the total number of patents.
Chemical patents share 62.7%, and the rest are DM
patents. Among chemical patents, resins and organic
compounds are the two largest subcategories, whereas
drug and surgery & medical instruments patents are most
presented ones in the DM category. Overall only 252, 821
(23.2%) patents have at least one NPR linked to a MED-
LINE paper (hereafter, scientific NPR or SNPR). This
fraction, however, varies significantly across the two cat-
egories: only 9.6% for chemical patents but 46.1% for
DM ones. The variability also holds at the subcategory
level. 29.1% of resins patents and 14.8% organic com-
pounds patents have SNPRs; by contrast, 80% of biotech-
nology patents cite MEDLINE papers, while 56.1% of
drugs patents and 21% of surgery & medical instruments
patents do so.
The second group of statistics is the total number of
NPRs and SNPRs. A total of 6, 948, 178 NPRs were
emanated from our corpus of patents, among which
2, 312, 621 (33.3%) are from chemical ones. More than
half (3, 574, 777; 51.4%) of the NPRs are SNPRs, which
are dominated by DM patents (2, 857, 497; 79.9%). The
rest (717, 280; 20.1%) are from chemical patents. There-
fore, although there is a larger portion of chemical
patents, they generate less amount of NPRs and are
less linked to science, when comparing to DM patents.
As for the subcategories, 49.3% and 42.5% of NPRs in
resins and organic compounds patents, respectively, refer
to MEDLINE papers. Biotechnology and drug patents
account for 88.8% of all the SNPRs in the DM category,
and 70.5% and 62.7% of their NPRs are scientific.
The last group of statistics is the average number of
SNPRs per patent. Here we average by both all patents
and patents with at least one SNPR, since the majority of
patents have no SNPRs. On average, a chemical patent
cites one MEDLINE paper; a DM patent cites 7 papers.
Such contrast, however, is much less evident if we use
the second averaging procedure. For patents that have at
least one SNPR, a chemical patent has 11 SNPRs while
15 for a DM patent. Delving into subcategories, there
is a large variation of the extent of linkage to science.
Organic compounds and resin patents on average cite 3.2
and 2.7 SNPRs respectively. A biotechnology patent has
on average 14 SNPRs, larger than any other categories.
In summary, all the overall statistics suggest that there
is a huge variation of the volume of science linkage, which
is dominated by biotechnology and drug patents. This
result is consistent with a previous small-scale study [6].
B. Overall characteristics over time
Next, we investigate how overall characteristics change
over time. Figure 2A shows a steady increase of the to-
tal number of granted patents over the examined period,
reaching from 21, 151 in 1976 to 52, 994 in 2012. Such in-
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FIG. 2. Overall characteristics of the patent-to-paper citation linkage over time. (A) The number of patents. (B) The fraction
of patents with at least one SNPR. (C) The total number of SNPRs. The red, dash-dotted line represent an exponential fit of
the total number of SNPRs from 1976 to 1998, Nt = 10
0.102·t−199.239. (D) The average number of SNPRs per patent.
crease is largely driven by the remarkable growth of DM
patents: a nearly ten-fold increase from only 2, 827 in
1976 to 26, 616 in 2012. The number of chemical patents,
on the other hand, has increased relatively slowly—44%.
We notice that there is a flatten period followed by a de-
creasing period from 1998 to 2005, for both chemical and
DM patents. Accompanying the increase of the raw num-
ber of patents is an increasing fraction of patents that cite
MEDLINE-indexed papers, as presented in Figure 2B.
In 1976, only 1.7% chemical and 6.8% DM patents had
SNPRs, and in 2012 the number reached to 21.3% and
58.7%, respectively. Figure 2C plots the total number
of patent-to-paper citations for patents granted in each
year, demonstrating a remarkable increase of science link-
age. We fit the growth from 1976 to 1998, obtaining
Nt = 10
0.102·t−199.239, where t is the calendar year and
Nt is total citations at t. This means that there is an
exponential growth of the total number of SNPRs, which
doubled every log10 2/0.102 = 2.94 years. DM patents,
again, drive the increase, and generate more SNPRs than
chemical patents across years. Finally, the increase of the
total number of SNPRs is not due to the increase of the
number of patents, but rooted at patents themselves, as
confirmed in Figure 2D which shows that the average
number of SNPRs per patent also increases. Yet, DM
patents have a faster increase than chemical patents.
We then add the country dimension to the analysis of
patent-to-paper citations. Figure 3A shows that the av-
erage number of SNPRs per patent has been increasing
for patents originated from the top 6 countries with the
largest number of patents. The extent, however, varies
by countries. For patents from Canada, the U.S., and the
U.K., the average increases faster than the overall case,
while for patents from France, Germany, and Japan, it in-
creases slower than the overall case. What is noteworthy
is that, starting from around 1996, Canada has surpassed
US in generating more SNPRs per patent. Figures 3B–G
further look at chemical and DM patents separately for
each of the top 6 countries. From these figures, we can
conclude that (1) across the top countries and categories,
there is an increasing citation linkage from life science
patents to biomedical research; and (2) DM patents ex-
hibit a faster increase than chemical patents across years
and countries.
C. Cited science
In this section, we explore the characteristics of pa-
pers that are cited by patents. We do so at the reference
level; that is, a paper that is cited by multiple patents is
counted multiple times, since the number of citations a
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paper receives from patents displays a heavy-tailed dis-
tribution, similar to the case of citations from papers [3].
First, we study the distributions of countries where
cited papers are produced. Figure 4A plots the fractions
of SNPRs authored by different countries over time. Here
we display the results separately for the six individual
countries that have the largest shares at 2012 and com-
bine the shares of the rest countries together. The distri-
bution at a particular year is derived as follows. We first
get all the patents granted in that year, and then count
the number of SNPRs produced by a given country and
normalize it by the total number of SNPRs cited by all
the patents in that year.
Figure 4A shows that the U.S. has been consistently
the largest producer of cited science, accounting for al-
most half (49%) of the SNPRs cited by patents in 2012.
Other top countries contribute to significantly smaller
fractions: 6.8% for the UK and 5.5% for Japan. Note
that here one may refrain to conclude that US science
has been increasingly cited by patents over time, because
the apparent increase of the fraction of US science could
simply due to an increasing portion of cited papers with
affiliation information available. This is corroborated by
the observation that the share of US science has been
stable since around 2000.
Figure 4B presents the fractions of cited references
that are produced by different types of institutions over
time, derived using the same procedure described above.
Universities have been consistently the largest producer;
57.7% of references that are cited by patents granted in
2012 are written by them. PRO, which includes insti-
tutes and government, are the second major player, con-
tributing to 9.8%. Public science, therefore, share 67.5%
of cited science in patents. Companies account for only
10%.
We also examine what are the funding agency that
supported the science cited by patents. Figure 4C shows
the portion of references that are supported by U.S. gov-
ernment and by NIH specifically. Since 1990, more than
30% of cited science are supported by U.S. government
and 20% by NIH. Table III further shows the top NIH
institutes by the amount of citations they receive.
The last effort to characterize the cited science is to ex-
amine to what extent they are basic or applied research.
We use the LS indicator described in Section II to mea-
sure the basicness of each paper. First, we plot in Fig-
ure 4D the histogram of LS for all the 14, 916, 511 MED-
LINE papers published between 1980 and 2012, illustrat-
ing how the entire biomedical literature is distributed
along the basic-applied spectrum. This serves as the
baseline set, against which we compare with the set of
papers cited by patents. We observe a bimodal distribu-
tion. Figure 4E shows the same plot, but for the refer-
ences that are cited by patents. We clearly observe that
the vast majority of these SNPRs situate at the basic end.
As a simple calibration, the bimodality in Figure 4D al-
lows us to empirically find a threshold th to separate the
two modes, which is 0.16. For 42.7% of all papers in Fig-
ure 4D, their score is smaller than th; By contrast, 85.2%
of SNPRS in Figure 4E fall into this category. This result
is robust if we instead look at the paper level. We fur-
ther make additional measurements to ascertain that the
observation is not driven by patents with many SNPRs.
For each patent, we calculate (1) the average value of LS
of its cited papers; and (2) the fraction of papers with
LS smaller than th. The results confirm that for the vast
majority of patents, most of their references are papers
from the basic side.
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TABLE III. Number of citations for top NIH IC.
IC Citations %
National Cancer Institute 416, 642 22.3
National Institute of General Medical Sciences 251, 171 13.5
National Institute of Allergy and Infectious Diseases 248, 842 13.3
National Heart, Lung, and Blood Institute 239, 139 12.8
National Institute of Diabetes and Digestive and Kidney Diseases 128, 801 6.9
National Institute of Neurological Disorders and Stroke 89, 904 4.8
National Institute of Child Health and Human Development 55, 184 3.0
National Center for Research Resources 54, 456 2.9
National Institute on Aging 49, 538 2.7
National Institute of Diabetes and Digestive and Kidney Diseases 40, 886 2.2
As a separate case study, we examine SNPRs from
patents that are associated with drugs approved by
the U.S. Food and Drug Administration (FDA). The
Hatch–Waxman Act mandates that drug innovators to
provide FDA with the list of patents that covers the
drug, and FDA included these patents in the Approved
Drug Products With Therapeutic Equivalence Evalua-
tions (also known as the Orange Book), although it is
not FDA’s task to actually evaluate the coverage. Such
patents may possess economic value for their owner to
8TABLE IV. Percentage of SNPRs originated from companies
to different types of institutions.
All Chemical DM
All US All US All US
EDU 48.1 47.6 47.7 47.7 48.2 47.6
PRO 13.4 13.0 14.8 14.5 13.1 12.6
COM 11.5 11.6 13.1 13.2 11.1 11.2
HOS 7.1 7.4 5.4 5.6 7.5 7.9
UNK 19.9 20.4 19.0 19.0 20.1 20.8
surpass the cost of the development of drugs, and at
the same time have the cure value for patients. We
get this list of patents from https://www.fda.gov/
drugs/informationondrugs/ucm129689.htm. We find
a much smaller number (4, 380) of such patents, which
cite 28, 512 SNPRs in our sample of papers. Figure 4F
shows that, although most (59.6%) of these SNPRs are
on the basic side, substantial amount are on the applied
side, yielding a bimodal distribution that is not present
in the overall case in Figure 4E. This may be related to
the underlying process of drug development where phar-
maceutical companies need to test the safety and effec-
tiveness of drugs on human—which is applied research
by definition.
D. Private-sector patents
In this section, we analyze science linkage of patents
assigned to companies. Table IV presents the overall per-
centages of citations originated from company patents to
papers authored by different types of affiliations. We ob-
serve that about 48% of citations form company patents
go to university papers, and this varies little if we focus
on chemical or DM patents separately or US patents only.
Other public research organization ranks the second, con-
tributing to 13–15%. Companies share only 11–13% of
the science base of their patents.
We further look at the science linkage of individual
companies. By way of example, Medtronic, a global med-
ical device company, owns the largest number (3, 565) of
DM patents in our sample. We find 11, 242 SNPRs in
those patents, among which 5, 824 are from universities,
579 from PRO, and only 297 from companies. The frac-
tion of SNPRs authored by the public science section
(universities and PRO), therefore, is 0.57. Table V ex-
tends this calculation to the top 10 companies that have
the largest number of chemical and DM patents, indicat-
ing a significant linkage to public science. We make one
more step and repeat this calculation to all the companies
whose patents have at least one SNPR. Figure 5 shows
the cumulative distributions of fraction of public science
SNPRs for all those companies, across the chemical and
DM categories. For more than 60% of companies, more
than half of SNPRs cited in their patents are from public
science.
0.0 0.2 0.4 0.6 0.8 1.0
Fraction of SNPRs from public science
0.0
0.2
0.4
0.6
0.8
1.0
CD
F
Chemical
Drugs & Medical
FIG. 5. Cumulative distributions of fraction of public science
SNPRs cited in company patents.
IV. DISCUSSION
We have uncovered several empirical findings regarding
how science linkage of US life science patents has changed
over a 37-year period. First, the overall growth of life
science patents are largely driven by the increase of drug
and medical patents. The volume of science linkage are
increasing exponentially, doubling every 2.9 years. The
increase happens in both chemical and drugs & medical
patents, as well as patents originated from different coun-
tries. Second, almost half of the SNPRs are produced in
the US; the majority of them are from the public science
sector. The overwhelming of them are basic research; yet,
the nuance is for patents associated with drugs, with a
non-negligible portion of them are applied research. US
government and NIH in particular continue to be found
as funders of research cited in patents. Third, for the
majority of companies, most of their patents cite public
science. Our results are important because they suggest
a continuous linkage of public science to private sector
inventions.
That the cited papers are more likely to be basic re-
search resonates with earlier results [6, 10], but appears
to be in a sharp contrast with a recent finding that de-
clares no relationship about whether basic or applied re-
search are more likely to be cited by patents [5]. The
inconsistency may be due to the difference in entities an-
alyzed. While we focused on papers, they focused on
grants and made the basic/applied dichotomy based on
grant abstracts. Furthermore, it remains to be seen to
what extent one short grant abstract can represent the
actual research performed and how different the level
scores are for papers produced under the same grant.
Future work is needed to model patent-to-paper knowl-
edge flow among different types of institutions and com-
pare how it is different from patent-to-patent knowledge
flow. That the science linkage is dominated by biotech-
nology and drug patents may suggest a finer level cat-
egorization of these patents that goes beyond existing
9TABLE V. The top 10 companies that own the largest number of chemical (left) and DM (right) patents. The Fraction columns
refer to the fraction of SNPRs that are authored by the public science section (universities and PRO).
Chemical DM
Company Patents Fraction Company Patents Fraction
BASF AG 8, 523 0.57 Medtronic Inc. 3, 565 0.57
Bayer AG 8, 450 0.42 Merck & Co., Inc. 3, 000 0.47
E. I. du Pont de Nemours and Company 7, 462 0.58 The Procter & Gamble Company 2, 349 0.52
General Electric Company 7, 276 0.73 Eli Lilly and Company 2, 314 0.42
Eastman Kodak Company 7, 028 0.46 Bayer AG 2, 258 0.54
Fuji Photo Film Co., Ltd. 6, 463 0.56 Pioneer Hi-Bred International, Inc. 2, 064 0.81
The Dow Chemical Company 5, 545 0.47 Cardiac Pacemakers, Inc. 1, 955 0.61
Ciba-Geigy Corporation 5, 059 0.31 Pfizer Inc. 1, 816 0.55
Hoechst AG 4, 468 0.36 Abbott Laboratories 1, 736 0.58
Shell Oil Company 4, 076 0.73 Monsanto Technology LLC 1, 696 0.80
schemes is needed. Future work can base the linkage
to science to cluster these patents and compare how
the data-driven derived clusters align with traditional
schemes.
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